Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Frontiers3d
iPSC-derived exosomes as amphotericin B carriers: a promising approach to combat cryptococcal meningitis
The hemolytic effects were tested using rabbit red blood cells. In a C57BL/6 J mouse model of cryptococcal ... Hepatotoxicity was assessed by measuring the levels of aspartate aminotransferase (AST), ...